BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LMY-920 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LMY-920\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07771361-3309@assetmemo.bio
DTSTAMP:20261121T005901Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:LMY-920: Phase 2 readout est. (NCT07771361)
DESCRIPTION:LMY-920\, phase 2\, Multiple Myeloma.\nStudy: BAFF CAR-T Cells 
 (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and
  Multiple Myeloma\nEstimated primary completion: December 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lmy-920#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07771361
URL:https://assetmemo.bio/drug/lmy-920#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
